PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20170731 230342
DJI 0006
IMG-20170806-WA0030
20170803 180027
20180129 142525
IMG-20170807-WA0030
  • October 10, 2024: Meeting of the Cardiovascular and Renal Drugs Advisory Committee - 10/10/2024
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-21 By FDA
  • User Fee Lists
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-21 By FDA
  • Counterfeit Medicine
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • PREA Non-Compliance Letters
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-20 By FDA
  • Internet Pharmacy Warning Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • DG Gel Card 125445, 125449, 125450 - 125457
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-20 By FDA
  • Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine,tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,raxtozinameran, Date of authorisation: 21/12/2020, Revision: 54, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20
  • Transderm Scōp (Scopolamine Transdermal System): Drug Safety Communication - FDA Adds Warning About Serious Risk of Heat-Related Complications with Antinausea Patch
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 34, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20
  • Pharmaceutical Quality Resources
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • News from Emerging Technology Program (ETP)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 26, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20
  • Human medicines European public assessment report (EPAR): Memantine Merz, memantine hydrochloride, Date of authorisation: 22/11/2012, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20
  • Human medicines European public assessment report (EPAR): Yorvipath, palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 5, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20
  • Human medicines European public assessment report (EPAR): Axura, memantine, Date of authorisation: 17/05/2002, Revision: 29, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20
Older posts
Theme: Scaffold by Danny Cooper.